These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
37 related articles for article (PubMed ID: 7949743)
21. Modest but increased penetration through damaged skin: an overview of the in vivo human model. Gattu S; Maibach HI Skin Pharmacol Physiol; 2011; 24(1):2-9. PubMed ID: 20588085 [TBL] [Abstract][Full Text] [Related]
22. Design and performance of a spreadsheet-based model for estimating bioavailability of chemicals from dermal exposure. Dancik Y; Miller MA; Jaworska J; Kasting GB Adv Drug Deliv Rev; 2013 Feb; 65(2):221-36. PubMed ID: 22285584 [TBL] [Abstract][Full Text] [Related]
23. Chemical penetration enhancers: a patent review. Ahad A; Aqil M; Kohli K; Chaudhary H; Sultana Y; Mujeeb M; Talegaonkar S Expert Opin Ther Pat; 2009 Jul; 19(7):969-88. PubMed ID: 19552513 [TBL] [Abstract][Full Text] [Related]
24. Topical delivery of cosmetics and drugs. Molecular aspects of percutaneous absorption and delivery. Förster M; Bolzinger MA; Fessi H; Briançon S Eur J Dermatol; 2009; 19(4):309-23. PubMed ID: 19443302 [TBL] [Abstract][Full Text] [Related]
25. Kinetics of cutaneous drug penetration. Franz TJ Int J Dermatol; 1983 Nov; 22(9):499-505. PubMed ID: 6358066 [No Abstract] [Full Text] [Related]
28. Percutaneous absorption. Brisson P Can Med Assoc J; 1974 May; 110(10):1182-5. PubMed ID: 4597976 [TBL] [Abstract][Full Text] [Related]
29. Vesicles as tools for the modulation of skin permeability. Dubey V; Mishra D; Nahar M; Jain NK Expert Opin Drug Deliv; 2007 Nov; 4(6):579-93. PubMed ID: 17970662 [TBL] [Abstract][Full Text] [Related]
30. Turning theory into practice: the development of modern transdermal drug delivery systems and future trends. Perumal O; Murthy SN; Kalia YN Skin Pharmacol Physiol; 2013; 26(4-6):331-42. PubMed ID: 23921120 [TBL] [Abstract][Full Text] [Related]
31. The effect of formulations and experimental conditions on in vitro human skin permeation-Data from updated EDETOX database. Samaras EG; Riviere JE; Ghafourian T Int J Pharm; 2012 Sep; 434(1-2):280-91. PubMed ID: 22634139 [TBL] [Abstract][Full Text] [Related]
32. [The skin and transdermal applications]. Pierard GE; Van Cromphaut I; Piérard-Franchimont C; Gaspard U; Kulbertus H Rev Med Liege; 1997 Sep; 52(9):585-8. PubMed ID: 9441341 [No Abstract] [Full Text] [Related]
33. Lag time in the dual sorption model for percutaneous absorption with finite skin-receptor boundary clearance. Twizell EH; Kubota K Math Biosci; 1994 Sep; 123(1):1-23. PubMed ID: 7949743 [TBL] [Abstract][Full Text] [Related]
34. Mathematical models for dermal drug absorption. Selzer D; Neumann D; Schaefer UF Expert Opin Drug Metab Toxicol; 2015; 11(10):1567-83. PubMed ID: 26166490 [TBL] [Abstract][Full Text] [Related]
35. Enhanced absorption through damaged skin: an overview of the in vitro human model. Gattu S; Maibach HI Skin Pharmacol Physiol; 2010; 23(4):171-6. PubMed ID: 20185974 [TBL] [Abstract][Full Text] [Related]
36. Mathematical and pharmacokinetic modelling of epidermal and dermal transport processes. Anissimov YG; Jepps OG; Dancik Y; Roberts MS Adv Drug Deliv Rev; 2013 Feb; 65(2):169-90. PubMed ID: 22575500 [TBL] [Abstract][Full Text] [Related]